UCB have announced the closing of sale of its Surface
Specialties business to Cytec Industries Inc. a global technology leader in specialty
chemicals and specialty materials, which occurs in just 5 months after the transaction was
The transaction amount is € 1,415 million of which € 1,190 million in cash and € 225
million in shares of Cytec.
Roch Doliveux, Chairman of the Executive Committee of UCB said: "I would like to pay
tribute to everyone involved with “Surface Specialties” for their skill and dedication and to
thank them for their contribution to UCB. We wish them well as part of Cytec.”
This sale concludes a number of strategic moves initiated with the acquisition of Celltech
last May, aimed at transforming UCB into a leading biopharmaceutical company.